Code intelligence

FDA-NDA216203 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA216203.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: INPEFA (SOTAGLIFLOZIN) — Type 1 - New Molecular Entity

Policy FDA-NDA216203 · Cardiology

High

Inpefa (sotagliflozin) is an oral tablet approved as a new molecular entity, placing it squarely in the Part D billing pathway for Medicare outpatient prescription drug coverage. As an SGLT2 inhibitor

View alert

Audit documentation

Building an audit file that includes FDA-NDA216203?

The Tripwire Audit Pack exports 12 months of Cardiology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Cardiology audit pack — $349One-time purchase · not a subscription